Fig 1: ICIs therapies increased HDAC-4 expression in HFC cells co-cultured with hPBMCs. HFC cells were incubated with or without hPBMC and treated for 48 h with Atezolizumab or Ipilimumab or Relatlimab or Nivolumab (100 nM). HDAC-4 expression (pg/ml), in HFC lysate, were quantified through selective ELISA kit, as described in methods. The data represent the mean ± SD of three independent experiments ***p < 0.001; **p < 0.01; *p < 0.05.